First-line trabectedin use boosts OS for advanced leiomyosarcoma
LMS-04 trial findings show a significant overall survival benefit with the use of induction and maintenance trabectedin alongside first-line doxorubicin for patients with inoperable, advanced leiomyosarcoma.
